OS Therapies details resale of 5.9M shares
OS Therapies Inc (OSTX) reported that on September 10, 2026 it filed a prospectus supplement with the SEC covering the resale of up to 5,874,094 shares of its common stock by selling stockholders under an existing Form S-3 registration statement.
Rhea-AI Filing Summary
OS Therapies Inc (OSTX) reported that on September 10, 2026 it filed a prospectus supplement with the SEC covering the resale of up to 5,874,094 shares of its common stock by selling stockholders under an existing Form S-3 registration statement. The supplement relates to a shelf registration originally filed on August 8, 2025 and declared effective on August 25, 2025. OS Therapies also provided a legal opinion from its counsel, Olshan Frome Wolosky LLP, regarding the validity of the shares, which is furnished as Exhibit 5.1 to this report.
Positive
- None.
Negative
- None.
Filing Explained
The September 10 8-K records registration for the resale of up to 5,874,094 shares by selling stockholders, not a completed sale; the shelf-registration framework creates capacity for future registered sales, so this filing alone does not establish a new company issuance.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Shares covered by prospectus supplement: 5,874,094 shares
Form S-3 file number: File No. 333-289443
Form S-3 filing date: August 8, 2025
+2 more
5 metrics
Shares covered by prospectus supplement
5,874,094 shares
Resale of common stock by selling stockholders under Form S-3
Form S-3 file number
File No. 333-289443
Registration statement that the prospectus supplement forms part of
Form S-3 filing date
August 8, 2025
Date the Form S-3 registration statement was filed with the SEC
Form S-3 effectiveness date
August 25, 2025
Date the Form S-3 registration statement was declared effective
Prospectus supplement and 8-K date
September 10, 2026
Date OS Therapies filed the prospectus supplement and this report
Key Terms
prospectus supplement, registration statement on Form S-3, resale, selling stockholders, +1 more
5 terms
prospectus supplement financial
"filed with the U.S. Securities and Exchange Commission a prospectus supplement"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
registration statement on Form S-3 regulatory
"forms a part of the Company’s registration statement on Form S-3"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
resale financial
"covers the resale from time to time of up to 5,874,094 shares"
Resale is the act of selling an item, asset, or security by someone who previously bought it rather than by the original maker or issuer. It matters to investors because resale activity affects how easily an investment can be sold, the price buyers are willing to pay, and the potential profit or loss — like selling a used car: condition, demand and market rules determine what you can get for it.
selling stockholders financial
"by the selling stockholders referenced in the Prospectus Supplement"
Selling stockholders are existing owners of a company's shares who are offering some or all of their holdings for sale, often as part of a public offering or secondary transaction. For investors this matters because such sales increase the number of shares available to buy, can signal how confident current owners are about future prospects, and may put short-term pressure on the stock price similar to more tickets being released for a popular event.
legal opinion regulatory
"to provide the legal opinion of its counsel, Olshan Frome Wolosky LLP"
FAQ
What did OS Therapies Inc (OSTX) announce in this Form 8-K?
OS Therapies Inc announced it filed a prospectus supplement with the SEC covering the resale of up to 5,874,094 shares of its common stock by selling stockholders under an existing Form S-3 registration statement.
What registration statement does the OS Therapies (OSTX) prospectus supplement relate to?
The prospectus supplement forms part of OS Therapies Inc’s registration statement on Form S-3 (File No. 333-289443), which was filed with the SEC on August 8, 2025 and declared effective on August 25, 2025.
What legal documents did OS Therapies Inc (OSTX) file with this 8-K?
OS Therapies Inc filed as exhibits a legal opinion from Olshan Frome Wolosky LLP regarding the legality of the shares (Exhibit 5.1) and a related consent from the same firm (Exhibit 23.1), with the consent included in the opinion.
When was the OS Therapies (OSTX) Form S-3 declared effective?
OS Therapies Inc’s registration statement on Form S-3 (File No. 333-289443) was declared effective on August 25, 2025 by the SEC, following its original filing on August 8, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
